SAN DIEGO--(BUSINESS WIRE)--Aug 18, 2022-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, “Arcturus Therapeutics”, Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced updated data from its ongoing ARCT-154 booster clinical trial. The new results demonstrate broad neutralizing antibody response against Omicron variants of concern, including BA.5, lasting for up to at least six months after administration of low-dose (5 mcg) ARCT-154 booster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005266/en/ Exploratory pseudovirus microneutralization (MNT) assay results...